Lopinavir-ritonavir for SARS-CoV-2 infection: a systematic review
By:
References
- Mohan BS, Nambiar V, et al., COVID-19: An Insight into SARS-CoV-2 Pandemic Originated at Wuhan City in Hubei Province of China. J Infect Dis Epidemiol, 2020 6:146. doi.org/<a href="https://doi.org/10.23937/2474-3658/1510146" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.23937/2474-3658/1510146</a>
- Vargas M., Servillo G., Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. European Review for Medical and Pharmacological Sciences, 2020. 24:p. 1.
- Cao, B., Wang, Y., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020, 382, 1787–1799., DOI : <a href="https://doi.org/10.1056/NEJMoa2001282" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJMoa2001282</a>
- Wang, J. Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model. 2020, 60, 3277–3286
- Nutho, B., Mahalapbutr, P., Why are Lopinavir and Ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry 2020, 59, 1769–1779.
- Yan D, Liu XY, Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalized non-critically ill patients with SARS-CoV-2 infection. Eur Respir J. 2020 Jul 16;56(1):2000799.
- Lecronier M, Beurton A, Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: An opportunistic retrospective analysis. Crit Care 2020;24:418.
- Kim JW, Kim EJ, Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Korean J Intern Med. 2020 Jun 16.
- Lee JE, Lee SO, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study. Antiviral Therapy. 2021;26(1-2):34–42. doi:<a href="https://doi.org/10.1177/13596535211039394" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/13596535211039394</a>
- Arabi YM, Gordon AC, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47(8):867–886. doi:<a href="https://doi.org/10.1007/s00134-021-06448-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00134-021-06448-5</a>
- Yueping Li, Zhiwei Xie, Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial, Clinical Advances, 2020, 1.
- Ye X.T., Luo Y.L, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur. Rev. Med. Pharm. Sci. 2020, 24, 3390–3396.
- Kocayiğit H, Özmen Süner K, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J Clin Pharm Ther. 2021;46(2):454–459. doi:<a href="https://doi.org/10.1111/jcpt.13305" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/jcpt.13305</a>
- Lowe DM, Brown LK, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomized, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. <em>PLoS Med</em>. 2022;19(10): e1004120. Published 2022 Oct 19. DOI: <a href="https://doi.org/10.1371/journal.pmed.1004120" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pmed.1004120</a>
Language: English
Page range: 131 - 136
Published on: May 2, 2024
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2024 Oana Rădună, Bianca Stepan, Emanuel Bobu, Andreea Blidaru, Bianca Cerbu, Iosif Marincu, Stefan Frent, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.